ChemoCentryx (NASDAQ:CCXI) Sets New 1-Year High at $51.50
ChemoCentryx (NASDAQ:CCXI) Sets New 1-Year High at $51.50
ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating)'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $51.50 and last traded at $51.46, with a volume of 19905 shares traded. The stock had previously closed at $50.98.
纳斯达克(代码：CCXI-GET Rating)周四交易中，ChemoCentryx公司的股价创下52周新高。该公司股价最高涨至51.5美元，最新报51.46美元，成交量为19905股。此前该股收盘价为50.98美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
A number of equities research analysts have issued reports on CCXI shares. SVB Leerink cut ChemoCentryx from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $64.00 to $52.00 in a research report on Friday, August 5th. Canaccord Genuity Group started coverage on ChemoCentryx in a research report on Thursday, August 4th. They set a "buy" rating and a $81.00 target price for the company. Stifel Nicolaus cut ChemoCentryx from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. StockNews.com raised ChemoCentryx from a "sell" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group cut ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 target price for the company. in a research report on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $65.25.
许多股票研究分析师发布了关于CCXI股票的报告。SVB Leerink在8月5日(星期五)的一份研究报告中将ChemoCentryx的评级从“跑赢大盘”下调至“市场表现”，并将该股的目标价从64.00美元下调至52.00美元。Cancord Genuity Group在8月4日星期四的一份研究报告中开始报道ChemoCentryx。他们为该公司设定了“买入”评级和81.00美元的目标价。Stifel Nicolaus在8月10日星期三的一份研究报告中将ChemoCentryx的评级从“买入”下调至“持有”。在8月10日星期三发布的一份研究报告中，StockNews.com将ChemoCentryx的评级从“卖出”上调至“持有”。最后，Canaccel Genuity Group将ChemoCentryx的评级从买入下调至持有，并为该公司设定了52.00美元的目标价。在8月5日星期五的一份研究报告中。六名投资分析师对该股的评级为持有，两名分析师给出了买入评级，一名分析师对该公司股票给予了强烈的买入评级。根据MarketBeat.com的数据，该公司目前的共识评级为持有，共识目标价为65.25美元。
ChemoCentryx Stock Up 1.0 %
ChemoCentryx股价上涨1.0%
The company has a quick ratio of 4.47, a current ratio of 4.54 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $3.67 billion, a P/E ratio of -26.97 and a beta of 1.67. The firm has a 50-day moving average price of $34.87 and a two-hundred day moving average price of $27.42.
该公司的速动比率为4.47，流动比率为4.54，债务权益比为0.02。该公司市值为36.7亿美元，市盈率为-26.97，贝塔系数为1.67。该公司的50日移动均线价格为34.87美元，200日移动均线价格为27.42美元。
Insider Activity
内幕活动
Institutional Inflows and Outflows
机构资金流入和流出
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Engineers Gate Manager LP raised its stake in ChemoCentryx by 4.4% during the first quarter. Engineers Gate Manager LP now owns 12,780 shares of the biopharmaceutical company's stock worth $320,000 after acquiring an additional 540 shares in the last quarter. Teacher Retirement System of Texas raised its stake in ChemoCentryx by 9.2% during the first quarter. Teacher Retirement System of Texas now owns 9,999 shares of the biopharmaceutical company's stock worth $251,000 after acquiring an additional 841 shares in the last quarter. Swiss National Bank raised its stake in ChemoCentryx by 0.8% during the fourth quarter. Swiss National Bank now owns 107,700 shares of the biopharmaceutical company's stock worth $3,921,000 after acquiring an additional 900 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in ChemoCentryx by 1.4% during the second quarter. UBS Asset Management Americas Inc. now owns 69,953 shares of the biopharmaceutical company's stock worth $1,733,000 after acquiring an additional 971 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in ChemoCentryx by 7.5% during the second quarter. Victory Capital Management Inc. now owns 14,077 shares of the biopharmaceutical company's stock worth $349,000 after acquiring an additional 981 shares in the last quarter. 81.09% of the stock is owned by institutional investors.
几家对冲基金和其他机构投资者最近买卖了该公司的股票。工程师门经理LP在第一季度将其在ChemoCentryx的持股增加了4.4%。工程师门管理公司现在拥有12,780股这家生物制药公司的股票，价值32万美元，此前在上个季度又购买了540股。德克萨斯州教师退休系统在第一季度将其在ChemoCentryx的持股增加了9.2%。德克萨斯州教师退休系统在上个季度额外购买了841股后，现在拥有9999股这家生物制药公司的股票，价值25.1万美元。瑞士国家银行在第四季度将其在ChemoCentryx的持股比例提高了0.8%。瑞士国家银行目前持有这家生物制药公司的107,700股股票，价值3921,000美元，上个季度又购入了900股。瑞银资产管理美洲公司(UBS Asset Management America Inc.)第二季度将其在ChemoCentryx的持股增加了1.4%。瑞银资产管理美洲公司(UBS Asset Management America Inc.)目前持有这家生物制药公司69,953股股票，价值1,733,000美元，此前该公司在上个季度增持了971股股票。最后，胜利资本管理公司在第二季度将其在ChemoCentryx的持股比例提高了7.5%。胜利资本管理公司目前持有这家生物制药公司14,077股股票，价值349,000美元，该公司在上个季度增持了981股股票。81.09%的股份由机构投资者持有。
About ChemoCentryx
关于ChemoCentryx
(Get Rating)
(获取评级)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
ChemoCentryx，Inc.是一家生物制药公司，专注于在美国开发和商业化治疗炎症性疾病、自身免疫性疾病和癌症的新药。它提供TAVNEOS(Avacopan)，一种口服的选择性C5aR抑制剂，用于治疗严重的抗中性粒细胞胞浆抗体相关小血管炎的成人患者。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- How will the chip ban affect Nvidia's stock?
- Is Best Buy A Sneaky Buy for Q4?
- Does The Bed Bath and Beyond Stock Rally Still Have Legs?
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- 免费获取StockNews.com关于ChemoCentryx(CCXI)的研究报告
- 芯片禁令将如何影响NVIDIA的股票？
- 百思买是第四季度的Sneaky Buy吗？
- Bed Bath和Beyond Stock Rally还有腿吗？
- 阿里巴巴-SW和百度集团-SW最终能在退市恐惧中重整旗鼓吗？
- 3种可能在你的观察名单上获得一席之地的材料类股
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
接受ChemoCentryx日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ChemoCentryx和相关公司的最新新闻和分析师评级的每日简要摘要。